Memorial Sloan Kettering Cancer Center

BioPontis Alliance’s business model. Credit: BioPontis Alliance. I don’t know how generic the situation is (but I suspect it’s similar in materials fields), but a story in Nature Biotechnology—”New models emerge for commercializing university assets,” by Nuala Moran (doi:10.1038/nbt0911-774)—describes some of the dilemmas and responses universities and private industries engaged in biotech development are coming…